Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


November 5, 2001 5 November, 2001

Pheromone Sciences' PSC Fertility Monitor™ U.S. Trial Reaches Full Enrollment


Pheromone Sciences Corp. (PHS: CDNX), today announced that it has achieved full enrollment of its USA based multi-center clinical trial for the PSC Fertility Monitor�¢ï¿½�¢.

The clinical trial, designed to test the efficacy of the PSC Fertility Monitor, is being carried out at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at the Women's Institute for Fertility, Endocrinology and Menopause in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology, Thomas Jefferson University Hospital.

"With the trial now fully enrolled, we intend to insure timely completion, data analysis, and reporting of results," said Christopher Neuman, President and CEO of Pheromone Sciences. "Results similar to those previously reported from the University of Toronto would provide the data required for marketing approval in the U.S."

Frost and Sullivan in their October 2001 report titled, Innovative Medical Devices Straight from Science Fiction wrote In North America, medical devices and technologies are converging to revolutionize the consumer self-care market". Mr. Neuman goes on to state, "Our PSC Fertility Monitor is one such example of this marriage of biotechnology and diagnostics to provide women with a reliable predictive approach to natural, cycle based family planning designed in a small wrist-watch sized device".

Subject to FDA approval, the PSC Fertility Monitor will be positioned in a marketplace of more than 5 million women across North America who are trying to conceive providing them with a personally customized, highly advanced diagnostic tool that can be used to provide up to 4 days advance notice of their pending ovulation. With this degree of advance notice, a women's ability to become pregnant increases significantly as most of the guesswork concerning timing of sexual relations to conceive can now be managed.

It is anticipated that many of the women currently using urine strips and basal temperature methods to determine their ovulation date would find the PSC Fertility Monitor appealing based on its ability to provide increased advance notice (4 days), ease of use, and non invasive approach.

"We are very pleased with the progress to date for this product. With the completion of the enrollment for the multi center trial coupled with the recent securing of the CE mark, the future marketability in North America and Europe for the PSC Fertility Monitor becomes more assured", stated Neuman.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT

Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com